SecurityEYEG / Eyegate Pharmaceuticals Inc. (30233M107)
President and CEOFROM STEPHEN
IndustryPharmaceutical Preparations
Institutional Owners20
Institutional Shares17,219,367 - 39.64%
Common Shares Outstanding43,439,130 shares (as of 2018-06-30)
Institutional Value$ 9,139,000 USD

Institutional Stock Ownership and Shareholders

EYEG / Eyegate Pharmaceuticals Inc. Institutional Ownership

Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) has 20 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 17,219,367 shares. Largest shareholders include Armistice Capital, Llc, Vanguard Group Inc, Barclays Plc, Us Bancorp \de\, IFP Advisors, Inc, Citadel Advisors Llc, Credit Suisse Ag/, Wedbush Securities Inc, Raymond James Financial Services Advisors, Inc., and Northern Trust Corp.
Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR TWO SIGMA SECURITIES, LLC 12,603 0 -100.00 5 0 -100.00
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 15,000 8
2017-02-10 13F-HR BlackRock Fund Advisors 10,254 10,352 0.96 18 17 -5.56
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 16,671 0 -100.00 6 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 728 728 0.00 1 1 0.00
2018-08-08 13F-HR US BANCORP \DE\ 40,650 40,650 0.00 15 22 46.67
2018-08-13 13F-HR Vantage Investment Advisors, LLC 6,500 6,500 0.00 2 3 50.00
2018-08-03 13F-HR WEDBUSH SECURITIES INC 20,000 20,000 0.00 8 11 37.50
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 9,226 9,226 0.00 4 4 0.00
2018-10-16 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 73,492 0 -100.00 39 0 -100.00
2018-08-14 13F-HR UBS Group AG 1,537 14,316 831.42 1 8 700.00
2018-08-14 13F-HR BARCLAYS PLC 52,569 65,500 24.60 20 35 75.00
2018-08-14 13F-HR Invesco Ltd. 11,612 6
2018-08-14 13F-HR MORGAN STANLEY 7,721 5,740 -25.66 3 3 0.00
2018-08-14 13F-HR ARMISTICE CAPITAL, LLC 1,192,000 16,802,500 1,309.61 453 8,905 1,865.78
2018-08-09 13F-HR BlackRock Inc. 635 635 0.00 0 0
2018-08-07 13F-HR IFP Advisors, Inc 26,800 26,800 0.00 10 14 40.00
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 56,628 25,851 -54.35 22 14 -36.36
2018-09-18 13F-HR/A NORTHERN TRUST CORP 14,553 14,553 0.00 6 8 33.33
2018-08-14 13F-HR CREDIT SUISSE AG/ 26,500 22,000 -16.98 10 12 20.00
2018-08-14 13F-HR Holistic Financial Partners 1,900 0 -100.00 1 0 -100.00
2018-08-14 13F-HR ROYAL BANK OF CANADA 12,356 12,355 -0.01 5 7 40.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 100 100 0.00 0 0
2018-08-14 13F-HR VANGUARD GROUP INC 73,949 114,949 55.44 28 61 117.86

Related News Stories

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

2018-09-07 seekingalpha
Discussion: On September 4, Recro Pharma (REPH) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the company now plans to submit a revised NDA by the end of this month. Suggestions offered by the FDA now guides the company to include revised labelling language and further information on extractable and leachable items. (123-10)

Your Daily Pharma Scoop: AC Immune Progresses, Keytruda's Further Approval, Novo Nordisk Phase 3 Positive

2018-08-22 seekingalpha
Discussion: AC Immune’s (ACIU) anti-Abeta vaccine development program recently reached two clinical milestones. To confirm the positive results of an earlier Phase 1 study of its candidate ACI-24 a Phase 2 trial has been initiated on patients with mild Alzheimer's disease (AD). Enrollment in the Phase 1b of a high dose cohort of the same candidate indicated in adults with Down syndrome with AD-like characteristics is now complete. (25-2)

Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate

2018-07-27 seekingalpha
Discussion: Biohaven Pharmaceutical Holding Company (BHVN) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expected to begin shortly. Following details of the study plan have been shared by the company. During the 48-week trial period, the 292-subject study will be randomized between trigriluzole and placebo. (10-4)

Reader Inquiry: Time To Buy EyeGate Pharmaceuticals?

2018-05-18 seekingalpha
Shares of fallen nearly 70% year to date but appear to be ready to fill the gap back to the psychologically important $1 level. (22-3)

CUSIP: 30233M107